Rising incidence of prostate cancer is expected to drive the growth of the United States Prostate Cancer Testing Market in the forecast period, 2018-2028
According to TechSci Research report, “United Prostate Cancer Testing Market - By Region, Competition Forecast and Opportunities, 2018-2028,” the United States Prostate Cancer Testing Market is expected to grow with an impressive CAGR during the forecast period 2018-2028. The rise in prevalence of prostate cancer and need for developing cancer testing solutions, and acquisitions, expansions, and strategic collaborations among key players are contributing to the market growth in the United States.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on “United States Prostate Cancer Testing Market”
United States Prostate Cancer Testing Market can be segmented into biomarker type, application, end user, region and competitive landscape.
Based on biomarker type, the market can be segmented into pre-biopsy/post-negative biopsy testing, initial evaluation: prostate-specific antigen (Total PSA, Free PSA), post-biopsy tissue testing. The pre-biopsy testing segment is expected to show an impressive growth in the forecast period due to the rising rate of cancer amongst men.
In terms of application, the market can be split into diagnostics biomarkers, and prognostics biomarkers. The diagnostics biomarkers segment is expected to show an impressive growth due to the rising R&D activity for the development of prostate cancer testing in the forecast period.
Based on the end user, the market can be classified into cancer research institutes, diagnostic laboratories, hospitals and clinics, ambulatory surgical center (ASCs), and others. The hospitals and clinics segment are expected to show an impressive growth in forecast period due to advanced healthcare facilities and growing expenditure in research and development in this segment
Major companies operating in the United States Prostate Cancer Testing Market include:
- F. Hoffmann-La Roche Ltd (Foundation Medicine, Inc.).
- Siemens Healthcare GmbH
- OPKO Health, Inc. (GenPath)
- Myriad Genetics Inc.
- NeoGenomics Laboratories
- Danaher. (Beckman Coulter, Inc.)
- Agilent Technologies, Inc.
- Abcam plc.
- Bio-Techne. (ExoDx)
- H.U. Group Holdings, Inc. (Fujeribio)
Customers can also request for 10% free customization on this report.
“United States Prostate Cancer Testing Market is expected to witness significant growth during the forecast period on account of increasing incidence of prostate cancer. An increase in awareness of preventive healthcare on account of growing incidence of chronic diseases further supports the demand for prostate cancer testing market in the United States. Additionally, increase in emergence of players developing new procedures of prostate cancer testing and treatment, is expected to create lucrative opportunities for the market growth in the next few years” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based global management consulting firm.
“United States Prostate Cancer Testing Market By Biomarker Type (Pre-Biopsy/Post-Negative Biopsy Testing, Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA), Post-Biopsy Tissue Testing), By Application (Diagnostics Biomarkers, Prognostics Biomarkers), By End User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals and Clinics, Ambulatory Surgical Center (ASCs), and Others), By Region, Competition Forecast & Opportunities, 2018-2028F,” has evaluated the future growth potential of United States prostate cancer testing market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States Prostate Cancer Testing Market.
Mr. Ken Mathews
708 Third Avenue,
New York – 10017
Email: [email protected]